Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
使用循环游离肿瘤 DNA 确定转移性去势抵抗性前列腺癌患者对多西紫杉醇反应的生物标志物
批准号：
406339
负责人：
Herberts Cameron
金额：
$1.27万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-12-01 至 2019-12-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary chemotherapy for late-stage prostate cancer is only effective in 45% of patients. However, there is currently no way of knowing in advance which patients will benefit from treatment, and which patients could avoid the side-effects of chemother
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determining biomarkers of response to docetaxel chemotherapy in men with metastatic castration resistant prostate cancer.
-
批准号：439993
-
项目类别：Studentship Programs
-
资助金额：$7.65万
-
财政年份：2020
-
负责人：Herberts Cameron
-
依托单位：
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
-
批准号：406704
-
项目类别：Miscellaneous Programs
-
资助金额：$0.44万
-
财政年份：2019
-
负责人：Herberts Cameron
-
依托单位：
Identifying the genomic and clinical features of AKT1 / PIK3CA mutant metastatic prostate cancer using circulating tumour DNA
-
批准号：412225
-
项目类别：
-
资助金额：$0.11万
-
财政年份：2019
-
负责人：Herberts Cameron
-
依托单位：
Circulating tumor DNA (ctDNA) profiling reveals a deficiency of biomarkers predictive of docetaxel response in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
批准号：391726
-
项目类别：
-
资助金额：$0.08万
-
财政年份：2018
-
负责人：Herberts Cameron
-
依托单位：
海外基金
